Global Prothrombin Complex Concentrate (PCC) Drug Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Prothrombin Complex Concentrate (PCC) Drug Market Research Report 2024
Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available. It may also be used in those with not enough of these factors due to other reasons such as warfarin therapy. It is given by slow injection into a vein.
According to Mr Accuracy reports’s new survey, global Prothrombin Complex Concentrate (PCC) Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prothrombin Complex Concentrate (PCC) Drug market research.
In Europe and United States market, key players of prothrombin complex concentrate (PCC) drug include CSL Behring, Grifols, Octapharma, Prothya Biosolutions, Takeda, etc. The top one player hold a share about 58%. United States is the largest market, has a share about 47%, followed by Germany, and France, with share 13% and 12%, separately.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prothrombin Complex Concentrate (PCC) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda
Segment by Type
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other
Hemophilia B
Acquired Coagulation Factor Deficiency
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prothrombin Complex Concentrate (PCC) Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Prothrombin Complex Concentrate (PCC) Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prothrombin Complex Concentrate (PCC) Drug market research.
In Europe and United States market, key players of prothrombin complex concentrate (PCC) drug include CSL Behring, Grifols, Octapharma, Prothya Biosolutions, Takeda, etc. The top one player hold a share about 58%. United States is the largest market, has a share about 47%, followed by Germany, and France, with share 13% and 12%, separately.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prothrombin Complex Concentrate (PCC) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda
Segment by Type
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other
Segment by Application
Hemophilia B
Acquired Coagulation Factor Deficiency
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prothrombin Complex Concentrate (PCC) Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices